Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 136.11 g/mol |
---|---|
Molecular Formula | C5H4N4O |
XLogP3 | -0.5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 136.03851076 g/mol |
Monoisotopic Mass | 136.03851076 g/mol |
Topological Polar Surface Area | 65.8 A^2 |
Heavy Atom Count | 10 |
Formal Charge | 0 |
Complexity | 275 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 10 | |
---|---|
Drug Name | Allopurinol |
PubMed Health | Allopurinol |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | Allopurinol is known chemically as 1,5-Dihydro-4H-pyrazolo[3,4-d ]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Its solubility in water at 37C is 80 mg/dL and is greater in an alkaline solution. Allopurinol Table... |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Watson Labs; Vintage Pharms; Ipca Labs; Mutual Pharm; Apotex; Accord Hlthcare; Sun Pharm Inds; Northstar Hlthcare; Mylan |
2 of 10 | |
---|---|
Drug Name | Allopurinol sodium |
PubMed Health | Allopurinol (Injection) |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only. It is available in vials as the sterile lyophi... |
Active Ingredient | Allopurinol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial |
Market Status | Prescription |
Company | Eurohlth Intl |
3 of 10 | |
---|---|
Drug Name | Aloprim |
PubMed Health | Allopurinol |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | ZYLOPRIM (allopurinol) has the following structural formula:ZYLOPRIM is known chemically as 1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allo... |
Active Ingredient | Allopurinol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial |
Market Status | Prescription |
Company | Mylan Institutional |
4 of 10 | |
---|---|
Drug Name | Lopurin |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Dr Reddys La |
5 of 10 | |
---|---|
Drug Name | Zyloprim |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Prometheus Labs |
6 of 10 | |
---|---|
Drug Name | Allopurinol |
PubMed Health | Allopurinol |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | Allopurinol is known chemically as 1,5-Dihydro-4H-pyrazolo[3,4-d ]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Its solubility in water at 37C is 80 mg/dL and is greater in an alkaline solution. Allopurinol Table... |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Watson Labs; Vintage Pharms; Ipca Labs; Mutual Pharm; Apotex; Accord Hlthcare; Sun Pharm Inds; Northstar Hlthcare; Mylan |
7 of 10 | |
---|---|
Drug Name | Allopurinol sodium |
PubMed Health | Allopurinol (Injection) |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only. It is available in vials as the sterile lyophi... |
Active Ingredient | Allopurinol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial |
Market Status | Prescription |
Company | Eurohlth Intl |
8 of 10 | |
---|---|
Drug Name | Aloprim |
PubMed Health | Allopurinol |
Drug Classes | Antigout, Urinary Stone Agent |
Drug Label | ZYLOPRIM (allopurinol) has the following structural formula:ZYLOPRIM is known chemically as 1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allo... |
Active Ingredient | Allopurinol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial |
Market Status | Prescription |
Company | Mylan Institutional |
9 of 10 | |
---|---|
Drug Name | Lopurin |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Dr Reddys La |
10 of 10 | |
---|---|
Drug Name | Zyloprim |
Active Ingredient | Allopurinol |
Dosage Form | Tablet |
Route | Oral |
Strength | 300mg; 100mg |
Market Status | Prescription |
Company | Prometheus Labs |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Allopurinol Zentiva
Dosage Form : Tabl
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Allopurinol Zentiva
Dosage Form : Tabl
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Allopurinol Zentiva
Dosage Form : Tabl
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Zyloric
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Zyloric
Dosage Form : TABLET
Dosage Strength : 300 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Zyloric
Dosage Form : Antic-calc Tablet
Dosage Strength : 100 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Zyloric
Dosage Form : Antic-calc Tablet
Dosage Strength : 100 mg
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Zyloric
Dosage Form : Antic-calc Tablet
Dosage Strength : 300 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Zyloric
Dosage Form : Antic-calc Tablet
Dosage Strength : 300 mg
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Zyloric 300
Dosage Form : Tabl
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : LOPURIN
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 1987-04-02
Application Number : 71586
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : LOPURIN
Dosage Form : TABLET;ORAL
Dosage Strength : 300MG
Approval Date : 1987-04-02
Application Number : 71587
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2013-05-06
Application Number : 203154
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 300MG
Approval Date : 2013-05-06
Application Number : 203154
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 1985-12-31
Application Number : 70268
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2025-04-14
Application Number : 215091
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : ZYLOPRIM
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 1982-01-01
Application Number : 16084
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2024-06-17
Application Number : 214443
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 1985-12-10
Application Number : 70150
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : ALLOPURINOL
Dosage Form : TABLET;ORAL
Dosage Strength : 300MG
Approval Date : 1986-04-14
Application Number : 70580
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2025-08-25
US Patent Number : 8003681
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 209203
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-08-25
Patent Expiration Date : 2025-08-25
US Patent Number : 8003681
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 209203
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-08-25
Patent Expiration Date : 2029-04-29
US Patent Number : 8546437
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-04-29
Patent Expiration Date : 2031-08-01
US Patent Number : 9216179
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-01
Patent Expiration Date : 2028-11-26
US Patent Number : 10183012
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-11-26
Patent Expiration Date : 2028-11-26
US Patent Number : 8283369
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-11-26
Patent Expiration Date : 2029-08-17
US Patent Number : 8084483
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-17
Patent Expiration Date : 2029-12-22
US Patent Number : 8357713
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-22
Patent Expiration Date : 2029-08-17
US Patent Number : 8084483
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-17
Patent Expiration Date : 2028-11-26
US Patent Number : 8283369
Drug Substance Claim :
Drug Product Claim :
Application Number : 209203
Patent Use Code : U-2104
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-11-26
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
10
PharmaCompass offers a list of Allopurinol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Allopurinol manufacturer or Allopurinol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Allopurinol manufacturer or Allopurinol supplier.
PharmaCompass also assists you with knowing the Allopurinol API Price utilized in the formulation of products. Allopurinol API Price is not always fixed or binding as the Allopurinol Price is obtained through a variety of data sources. The Allopurinol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Uritas manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Uritas, including repackagers and relabelers. The FDA regulates Uritas manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Uritas API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Uritas manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Uritas supplier is an individual or a company that provides Uritas active pharmaceutical ingredient (API) or Uritas finished formulations upon request. The Uritas suppliers may include Uritas API manufacturers, exporters, distributors and traders.
click here to find a list of Uritas suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Uritas DMF (Drug Master File) is a document detailing the whole manufacturing process of Uritas active pharmaceutical ingredient (API) in detail. Different forms of Uritas DMFs exist exist since differing nations have different regulations, such as Uritas USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Uritas DMF submitted to regulatory agencies in the US is known as a USDMF. Uritas USDMF includes data on Uritas's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Uritas USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Uritas suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Uritas Drug Master File in Japan (Uritas JDMF) empowers Uritas API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Uritas JDMF during the approval evaluation for pharmaceutical products. At the time of Uritas JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Uritas suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Uritas Drug Master File in Korea (Uritas KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Uritas. The MFDS reviews the Uritas KDMF as part of the drug registration process and uses the information provided in the Uritas KDMF to evaluate the safety and efficacy of the drug.
After submitting a Uritas KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Uritas API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Uritas suppliers with KDMF on PharmaCompass.
A Uritas CEP of the European Pharmacopoeia monograph is often referred to as a Uritas Certificate of Suitability (COS). The purpose of a Uritas CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Uritas EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Uritas to their clients by showing that a Uritas CEP has been issued for it. The manufacturer submits a Uritas CEP (COS) as part of the market authorization procedure, and it takes on the role of a Uritas CEP holder for the record. Additionally, the data presented in the Uritas CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Uritas DMF.
A Uritas CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Uritas CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Uritas suppliers with CEP (COS) on PharmaCompass.
A Uritas written confirmation (Uritas WC) is an official document issued by a regulatory agency to a Uritas manufacturer, verifying that the manufacturing facility of a Uritas active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Uritas APIs or Uritas finished pharmaceutical products to another nation, regulatory agencies frequently require a Uritas WC (written confirmation) as part of the regulatory process.
click here to find a list of Uritas suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Uritas as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Uritas API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Uritas as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Uritas and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Uritas NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Uritas suppliers with NDC on PharmaCompass.
Uritas Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Uritas GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Uritas GMP manufacturer or Uritas GMP API supplier for your needs.
A Uritas CoA (Certificate of Analysis) is a formal document that attests to Uritas's compliance with Uritas specifications and serves as a tool for batch-level quality control.
Uritas CoA mostly includes findings from lab analyses of a specific batch. For each Uritas CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Uritas may be tested according to a variety of international standards, such as European Pharmacopoeia (Uritas EP), Uritas JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Uritas USP).